Insider Buying: Bonk (NASDAQ:BNKK) Director Purchases 9,000 Shares of Stock

Bonk, Inc. (NASDAQ:BNKK) Director Mitchell Austin Rudy bought 9,000 shares of the firm’s stock in a transaction on Monday, July 13th. The stock was acquired at an average price of $1.21 per share, for a total transaction of $10,890.00. Following the transaction, the director owned 95,000 shares of the company’s stock, valued at approximately $114,950. The trade was a 10.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Mitchell Austin Rudy also recently made the following trade(s):

• On Thursday, July 2nd, Mitchell Austin Rudy bought 11,659 shares of Bonk stock. The stock was bought at an average cost of $1.47 per share, with a total value of $17,138.73.
• On Monday, June 22nd, Mitchell Austin Rudy purchased 7,500 shares of Bonk stock. The stock was bought at an average price of $1.56 per share, for a total transaction of $11,700.00.
• On Tuesday, June 16th, Mitchell Austin Rudy purchased 2,500 shares of Bonk stock. The shares were bought at an average cost of $1.32 per share, for a total transaction of $3,300.00.
• On Wednesday, June 10th, Mitchell Austin Rudy acquired 12,000 shares of Bonk stock. The shares were bought at an average price of $1.37 per share, with a total value of $16,440.00.

Bonk Price Performance

Shares of NASDAQ:BNKK opened at $1.18 on Tuesday. Bonk, Inc. has a one year low of $1.14 and a one year high of $46.90. The company has a market cap of $9.44 million, a price-to-earnings ratio of -0.25 and a beta of 1.89. The firm has a 50 day simple moving average of $1.73 and a 200 day simple moving average of $2.71.

Bonk (NASDAQ:BNKK) last posted its earnings results on Wednesday, May 13th. The company reported ($0.23) earnings per share for the quarter. Bonk had a negative return on equity of 148.62% and a negative net margin of 838.37%.The company had revenue of $0.79 million for the quarter.

Analyst Ratings Changes

Several equities analysts have commented on the company. Wall Street Zen upgraded Bonk from a “sell” rating to a “hold” rating in a research report on Saturday, July 4th. Weiss Ratings cut Bonk from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bonk presently has an average rating of “Sell”.

Institutional Trading of Bonk

A number of institutional investors and hedge funds have recently bought and sold shares of BNKK. State Street Corp acquired a new position in Bonk during the 4th quarter worth about $33,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Bonk in the fourth quarter valued at about $37,000. Jane Street Group LLC bought a new position in shares of Bonk during the fourth quarter worth about $96,000. Finally, Geode Capital Management LLC bought a new position in shares of Bonk during the fourth quarter worth about $128,000. 12.55% of the stock is currently owned by institutional investors and hedge funds.

About Bonk

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.